Oncology

Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

October 6, 2009
Mieke Van Hemelrijck

Mieke Van Hemelrijck

Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever type—for their prostate cancer.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Audio Journal of Oncology – Prostate Cancer Special Edition 2005

    • Reporting from: - 2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida In this edition: Will they or won’t they

  • Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

    • Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27

  • Audio Journal of Oncology 12.9, December 2004

    • Reporting from: - 4th European Breast Cancer Conference, March 16-20, 2004, Hamburg - 6th International Symposium on Hodgkin’s Lymphoma - 16th EORTC-NCI-AACR Symposium

    Post a comment